26 June 2024 - The approval of Xpovio by the NHIS in South Korea is the fourth national reimbursement in the Antengene markets after mainland of China, Australia and Singapore.

Antengene today announced that South Korea's National Health Insurance Service (NHIS) has approved the reimbursement of Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma. Xpovio will be officially included into the national reimbursed drugs list of South Korea on 1 July 2024.

Read Antengene press release